We are live on ! Find out more
TARA icon

Protara Therapeutics

82 hedge funds and large institutions have $114M invested in Protara Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

8% more funds holding

Funds holding: 76 → 82 (+6)

8% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 26

9.05% less ownership

Funds ownership: 77.02% → 67.97% (-9%)

30% less call options, than puts

Call options by funds: $183K | Put options by funds: $261K

64% less capital inflows, than outflows

Capital inflows: $5.98M | Capital outflows: $16.6M

Holders
82
Holders Change
+6
Holders Change %
+7.89%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
24
Reduced
26
Closed
8
Calls
$183​K
Puts
$261​K
Net Calls
-⁠$78​K
Net Calls Change
-⁠$83​K

TARA Hedge Fund Activity: Q3 2025 in Review

82 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2025, worth a combined $114M — up 27% from $90.1M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TARA positions and 8 closed out — a net gain of 7 holders — while 24 added to existing stakes and 26 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.44M. The largest seller was RA Capital Management, exiting entirely with an estimated $3.15M sold.

  • 82 institutional investors held Protara Therapeutics (TARA) as of Q3 2025, up from 76 in Q2 2025.
  • Funds reported $114M of Protara Therapeutics stock for Q3 2025, up 27% quarter-over-quarter.
  • 15 funds opened new Protara Therapeutics positions in Q3 2025 and 8 closed out, a net change of +7 holders.
  • The largest Protara Therapeutics buyer in Q3 2025 was Driehaus Capital Management, an estimated $1.44M added.
  • The largest Protara Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $3.15M sold.

Based on aggregated 13F filings for Q3 2025.